Areas of Focus
- 翻译后修饰与代谢性疾病机制
- 基于靶点的抗体、小分子药物研发
Work Experience
- 2015.8~2017.6 武汉大学 基础医学院 博士后
- 2017.7~2021.7 武汉大学中南医院 助理研究员
- 2021.8~今 武汉大学 基础医学院 特聘研究员
Academic Background & Achievements
- 2005.9~2009.6 成都理工大学 生物工程 本科
- 2009.9~2015.7 武汉大学 遗传学 博士
Publications
- A kinome screen reveals that Nemo-like Kinase is a key upstream regulator of hepatic gluconeogenesis, 姬燕晓等, 2021
- Hepatic Regulator of G protein Signaling 5 Ameliorates NAFLD by Suppressing TAK1-JNK/p38 Signaling, 王佳等, 2020
- Milk Fat Globule–Epidermal Growth Factor–Factor 8 Improves Hepatic Steatosis and Inflammation, 张丽等, 2020
- Metformin Is Associated with Higher Incidence of Acidosis, but Not Mortality, in Individuals with COVID-19 and Pre-existing Type 2 Diabetes, 程晓等, 2020
- F-box/WD Repeat-Containing Protein 5 Mediates the Ubiquitination of Apoptosis Signal-Regulating Kinase 1 and Exacerbates Nonalcoholic Steatohepatitis in Mice, 白丽等, 2019
- Hepatic IRF2BP2 Mitigates Nonalcoholic Fatty Liver Disease by Directly Repressing the Transcription of ATF3, 方佳等, 2019
- The deubiquitinating enzyme cylindromatosis mitigates nonalcoholic steatohepatitis, 姬燕晓等, 2018
- Targeting CASP8 and FADD-like apoptosis regulator ameliorates nonalcoholic steatohepatitis in mice and nonhuman primates, 王培霞等, 2017
- The ubiquitin E3 ligase TRAF6 exacerbates pathological cardiac hypertrophy via TAK1-dependent signalling, 姬燕晓等, 2016
- Suppressor of IKKvarepsilon is an essential negative regulator of pathological cardiac hypertrophy, 邓康强等, 2016